Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1960 5
1961 1
1962 5
1963 2
1964 2
1966 1
1967 4
1968 2
1969 1
1970 1
1972 1
1973 1
1976 1
1979 1
1982 3
1983 8
1984 9
1985 2
1986 6
1987 5
1988 4
1989 7
1990 8
1991 2
1992 6
1993 7
1994 4
1995 6
1996 4
1997 8
1998 2
1999 2
2000 5
2001 4
2002 1
2003 2
2004 2
2005 1
2006 2
2007 3
2008 1
2009 3
2010 7
2011 3
2012 5
2013 3
2014 3
2015 2
2016 2
2017 3
2018 2
2019 6
2020 5
2021 2
2022 4
2023 3
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

184 results

Results by year

Filters applied: . Clear all
Page 1
UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.
Laheurte C, Boullerot L, Ndao B, Malfroy M, Queiroz L, Guillaume P, Loyon R, Seffar E, Gravelin E, Renaudin A, Jacquin M, Meurisse A, Vernerey D, Ghiringhelli F, Godet Y, Genolet R, Jandus C, Borg C, Adotévi O. Laheurte C, et al. Cell Rep Med. 2025 Jul 15;6(7):102196. doi: 10.1016/j.xcrm.2025.102196. Epub 2025 Jun 20. Cell Rep Med. 2025. PMID: 40543509 Free PMC article. Clinical Trial.
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).
Vienot A, Jacquin M, Rebucci-Peixoto M, Pureur D, Ghiringhelli F, Assenat E, Hammel P, Rosmorduc O, Stouvenot M, Allaire M, Bouattour M, Regnault H, Fratte S, Raymond E, Soularue E, Husson-Wetzel S, Di Martino V, Muller A, Clairet AL, Fagnoni-Legat C, Adotevi O, Meurisse A, Vernerey D, Borg C. Vienot A, et al. BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0. BMC Cancer. 2023. PMID: 37516867 Free PMC article. Clinical Trial.
Naturally Occurring Telomerase-Specific CD4 T-Cell Immunity in Melanoma.
Nardin C, Laheurte C, Puzenat E, Boullerot L, Ramseyer M, Marguier A, Jacquin M, Godet Y, Aubin F, Adotevi O. Nardin C, et al. J Invest Dermatol. 2022 Feb;142(2):435-444. doi: 10.1016/j.jid.2021.07.160. Epub 2021 Aug 2. J Invest Dermatol. 2022. PMID: 34352265 Free article.
Exposure-response analysis of Raltitrexed assessing liver toxicity.
Royer B, Schmitt A, Nguyen T, Paillard MJ, Jary M, Demarchi M, Vernerey D, Henriques J, Jacquin M, Borg C, Kim S. Royer B, et al. Br J Clin Pharmacol. 2021 Mar;87(3):1327-1337. doi: 10.1111/bcp.14519. Epub 2020 Sep 4. Br J Clin Pharmacol. 2021. PMID: 32789966 Free article. Clinical Trial.
184 results